Zidesamtinib is a small molecule commercialized by Nuvalent, with a leading Phase II program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Zidesamtinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Zidesamtinib is expected to reach an annual total of $60 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zidesamtinib Overview
NVL-520 is under development for the treatment of ROS1 positive non-small cell lung cancer, other advanced solid tumors and glioblastoma multiforme. It is administered through oral route in the form of film-coated tablets. The drug candidate acts by targeting proto oncogene tyrosine protein kinase (ROS1).
Nuvalent Overview
Nuvalent is a clinical-stage biopharmaceutical company that develops innovative small molecules for cancer. The company’s pipeline products include zidesamtinib (NVL-520) a ROS1-selective inhibitor; NVL-655 a brain-penetrant anaplastic lymphoma kinase (ALK)-selective inhibitor; NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor. Its lead candidates treat solid tumors, non-small cell lung cancer (NSCLC) and brain metastases. The company works in collaboration with contract research organizations (CROs), medical institutions and contract manufacturing organizations (CMOs) to conduct and support preclinical studies and clinical trials. Nuvalent is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$149.5 million in FY2023, compared to an operating loss of US$86.1 million in FY2022. The net loss of the company was US$126.2 million in FY2023, compared to a net loss of US$81.9 million in FY2022.
For a complete picture of Zidesamtinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
